Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Oct 18;25(3):577–586. doi: 10.1016/j.bbmt.2018.10.011

Figure 2. Cumulative incidence of CMV infection, not including (A,C,E) and including (B,D,F) systemic steroids as a competing risk.

Figure 2.

A and B: 100-day cumulative incidence of CMV infection by donor/recipient serostatus. C and D: 100-day cumulative incidence of CMV infection by graft source. E and F: 100-day cumulative incidence of CMV infection by T-cell manipulation strategy.